MedTrace Logo

COVID-19 International Drug Pregnancy Registry

NCT05013632 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-09-26

No results posted yet for this study

Summary

The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.

Conditions

  • Covid19

Interventions

DRUG

Antiviral Agents

Antiviral medications indicated for the treatment of mild to severe COVID-19

DRUG

Monoclonal antibody

Monoclonal antibodies indicated for the treatment of mild to severe COVID-19

Sponsors & Collaborators

  • Pregistry

    lead INDUSTRY

Principal Investigators

  • Cheryl Renz, MD · Pregistry

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05013632 on ClinicalTrials.gov